Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Hisato Kawakami"'
Autor:
Shinichiro Suzuki, Kazuya Fukuoka, Hisato Kawakami, Soichi Fumita, Kazuhiko Nakagawa, Hidetoshi Hayashi, Chihiro Sato, Kazuko Sakai, Shigeki Shimizu, Tatsuya Okuno, Koji Haratani, Akihiko Ito, Yoshikane Nonagase, Kazumasa Saigoh, Kimio Yonesaka, Hisashi Handa, Takeshi Yoshida, Masayuki Takeda, Tetsuya Mitsudomi, Kazuto Nishio, Takayuki Takahama, Naoki Takegawa, Satomi Watanabe, Kaoru Tanaka
Publikováno v:
The Oncologist
Background Implementation of personalized medicine requires the accessibility of tumor molecular profiling in order to allow prioritization of appropriate targeted therapies for individual patients. Our aim was to study the role of comprehensive geno
Autor:
H. Takeda, Tomohiko Ukai, Masakazu Yamamoto, Makoto Ueno, Steven M. Strasberg, René Adam, Mariano E Giménez, Takuro Mizukami, Naohiro Okano, Palepu Jagannath, Ho-Seong Han, Katsunori Sakamoto, Masato Ozaka, Takayuki Ueno, Susumu Hijioka, Koji Asai, Yoo Seok Yoon, Keita Wada, Keiji Sano, Toru Beppu, Satoru Shikata, Takako Eguchi Nakajima, Tsutomu Tabata, Shingo Yamashita, Do Youn Oh, Yoichi Naito, Tadahiro Takada, Taizo Hibi, Junji Furuse, Masayuki Ohtsuka, Koichi Hayano, Tsann Long Hwang, Hee-Jung Wang, Masahiro Yoshida, Teijiro Hirashita, Nozomu Sakai, Shao Ciao Luo, Hisato Kawakami, Yukio Iwashita, Ryusei Matsuyama, Michael G. Sarr, Olivier Scatton, Yasuhisa Mori
Publikováno v:
Journal of Hepato-Biliary-Pancreatic Sciences. 28:1-25
Background Hepatectomy is standard treatment for colorectal liver metastases; however, it is unclear whether liver metastases from other primary cancers should be resected or not. The Japanese Society of Hepato-Biliary-Pancreatic Surgery therefore cr
Autor:
Kaoru Tanaka, Ryoji Kato, Hitomi Sakai, Masayuki Takeda, Kimio Yonesaka, Hisato Kawakami, Kazuhiko Nakagawa, Koji Haratani, Hidetoshi Hayashi, Kazuto Nishio, Kazuko Sakai
Publikováno v:
British Journal of Cancer
Background Cancer-associated fibroblasts (CAFs) in the tumour microenvironment (TME) suppress antitumour immunity, and the tyrosine kinase inhibitor nintedanib has antifibrotic effects. Methods We performed a preclinical study to evaluate whether nin
Autor:
Hisato Kawakami, Hiroko Hasegawa, Ken Kato, Hiroki Hara, Tomohiro Nishina, Naoki Izawa, Tadamichi Denda, Yoshinori Kagawa, Akihito Tsuji, Yoshiaki Nakamura, Izumi Miki, Toshikazu Moriwaki, Yasutoshi Sakamoto, Kentaro Yamazaki, Eiji Oki, Takeshi Kato, Tomohiro Nishida, Satoshi Yuki, Hiromichi Ebi, Wataru Okamoto, Satoshi Fujii, Toshiki Masuishi, Manabu Shiozawa, Takayuki Yoshino, Hiroya Taniguchi, Taito Esaki
Publikováno v:
Cancer Science
FMS‐like tyrosine kinase 3 (FLT3) plays a key role in hematopoiesis. However, the oncogenic role of FLT3 amplification in patients with metastatic colorectal cancer (mCRC) remains unclear. Here, we aimed to evaluate the characteristics, prognosis,
Autor:
Keisho Chin, Shigenori Kadowaki, Masanobu Takahashi, Hiroki Hara, Ken Kato, Ryu Ishihara, Satoru Motoyama, Yasuo Hamamoto, Hisato Kawakami, Manabu Muto, Yuichiro Nakashima, Morihito Okada, Yuichiro Doki, Mamoru Kodani, Yuko Kitagawa, Yutaro Kubota, Takashi Ogata, Masahiro Tsuda
Publikováno v:
Esophagus
Background The efficacy and safety of nivolumab versus chemotherapy was evaluated in the Japanese subpopulation from the overall intent-to-treat (ITT) population of the ATTRACTION-3 trial conducted in patients with advanced esophageal squamous cell c
Autor:
Kazuhiro Nishikawa, Kazumasa Fujitani, Yutaka Kimura, Atsushi Takeno, Yoichi Makari, Jin Matsuyama, Ryohei Kawabata, Taroh Satoh, Daisuke Sakai, Hisato Kawakami, Toshio Shimokawa, Tetsuji Terazawa, Yukinori Kurokawa
Publikováno v:
Gastric Cancer. 24:428-434
Cisplatin plus S-1 (CS) is the standard first-line chemotherapy for advanced gastric cancer (AGC) in Japan. A previous phase III trial showed that docetaxel plus S-1 (DS) was effective for AGC without measurable lesions, but no studies have compared
Autor:
Kohei Shitara, Hisato Kawakami, Jeeyun Lee, DESTINY-Gastric Investigators, Hyun-Cheol Chung, Akihito Kojima, Daisuke Sakai, Min-Hee Ryu, Masahiro Sugihara, Kensei Yamaguchi, Hiroshi Yabusaki, Satoru Iwasa, Takahiro Kamio, Naotoshi Sugimoto, Yung-Jue Bang, Yoshinori Kawaguchi, Kaku Saito
Publikováno v:
New England Journal of Medicine. 382:2419-2430
Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. The drug may have efficac
Autor:
Yutaka Kimura, Hisato Kawakami, Masahiro Goto, Youichi Makari, Takao Tamura, Naotoshi Sugimoto, Jin Matsuyama, Yukinori Kurokawa, Toshimasa Tsujinaka, Daisuke Sakai, Shunji Endo, Kazumasa Fujitani, Yusuke Akamaru, Toshio Shimokawa, Shigeyuki Tamura, Taroh Satoh
Publikováno v:
International Journal of Clinical Oncology. 25:1635-1643
We previously reported the HERBIS-4A phase II trial comparing S-1 plus cisplatin (SP) with capecitabine plus cisplatin (XP) in chemotherapy-naive patients with HER2-negative advanced gastric cancer (GC). We performed a pooled analysis of HERBIS-4A an
Autor:
Hisato Kawakami, Naotoshi Sugimoto, Takeshi Kato, Taroh Satoh, Masaki Tsujie, Shu Okamura, Yukihiko Tokunaga, Shigeyoshi Iwamoto, Takashi Ohta, Masato Nakamura, Masahito Kotaka, Taishi Hata, Toshio Shimokawa, Hideyuki Mishima, Yukinori Kurokawa, Yasuhiro Miyake, Toshio Otsuji, Masahiro Goto
Publikováno v:
International Journal of Clinical Oncology. 25:1291-1298
Older or frail patients are often underrepresented in clinical trials for metastatic colorectal cancer (mCRC). We here assessed the efficacy and safety of 5-fluorouracil (5-FU)–leucovorin plus bevacizumab in such patients. The study (OGSG 0802) was
Autor:
Keiji Furuuchi, Toshimitsu Uenaka, Ryoji Kato, Hitomi Sakai, Yuta Onodera, Elizabeth B. Somers, Hisato Kawakami, Takeshi Teramura, Kazuhiko Nakagawa
Publikováno v:
Clinical and Translational Medicine
Clinical and Translational Medicine, Vol 11, Iss 6, Pp n/a-n/a (2021)
Clinical and Translational Medicine, Vol 11, Iss 6, Pp n/a-n/a (2021)
Background The main function of folate receptor α (FOLRα) has been considered to mediate intracellular folate uptake and induce tumor cell proliferation. Given the broad spectrum of expression among malignant tumors, including gastric cancer (GC) b